AbbVie and Galapagos extend deal
May 21, 2013Sales and Marketing AbbVie, Crohn's, Galapagos
AbbVie and Belgian biotech Galapagos have bolted on a development programme for Crohn’s disease to the selective JAK1 inhibitor they …
Working with the NHS in austerity
May 20, 2013Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing NHS, atkin, austerity, reforms, wellards
The National Health Service, perhaps the UK’s most deeply loved institution, is facing a double threat. On one hand, there …
Promise for Lundbeck and Takeda’s depression drug
May 20, 2013Research and Development, Sales and Marketing Lexapro, Lundbeck, Takeda, cymbalta, depression, lilly
Takeda and Lundbeck’s treatment for major depressive disorder has demonstrated a significant improvement in patients’ symptoms during trials. Brintellix (Vortioxetine) …
Biotec Services expands presence in Israel
May 20, 2013Research and Development, Sales and Marketing Biotec
Clinical supplies firm Biotec Services International has expanded its presence in Israel with the appointment of a new Israeli agent. …
Excipient certification scheme launches in US
May 17, 2013Manufacturing and Production EXCiPACT, GMP
A certification scheme for pharmaceutical excipients to make it easier for drugmakers to source materials from reliable suppliers made its …
NICE chairman joins biotech Board
May 17, 2013Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Intra-Cellular Therapies, NICE, Rawlins
Biotech firm Intra-Cellular Therapies has appointed former NICE chairman Professor Sir Michael Rawlins to its Board of directors. Rawlins was …
South Korea eyeing criminal charges over J&J plant failures
May 17, 2013Manufacturing and Production J&J, JJ, Janssen, Korea, MFDS
The chief executive of Johnson & Johnson’s South Korean subsidiary could be facing criminal charges over quality lapses at a …
Government ‘joins-up’ system
May 15, 2013Sales and Marketing NHS, NICE, government, king's fund
The government has launched its plans to create ‘a truly joined-up system’ for the provision of health and social care …
Elan signs $1 billion finance deal with Theravance
May 15, 2013Research and Development, Sales and Marketing Elan, Theravance, royalty pharma
Elan has struck a novel deal with Theravance which gives it a share of potential future royalties from its respiratory …
Hospira Reappoints chief scientific officer
May 15, 2013Manufacturing and Production, Research and Development, Sales and Marketing Hospira
Injectable drugs and infusion tech firm Hospira has announced that Sumant Ramachandra has been reappointed to his role as senior …
Pfizer targets Newcastle
May 15, 2013Research and Development, Sales and Marketing ABPI, Cameron, NHS, Newcastle, Pfizer
Pfizer has earmarked Newcastle Hospitals NHS Foundation Trust as one of 60 sites worldwide to take part in a key …
Amgen and Zhejiang sign cancer deal
May 14, 2013Sales and Marketing Amgen, Cancer, Zhejiang
Amgen has signed a joint venture deal with Chinese firm Zhejiang Beta Pharma to commercialise oncology drug Vectibix. The companies …
Optimer Pharmaceuticals appoints chief operating officer
May 14, 2013Manufacturing and Production, Research and Development, Sales and Marketing
Biopharma firm Optimer Pharmaceuticals has announced the appointment of Eric Sirota as chief operating officer. “Eric has tremendous experience and …
Ranbaxy unit fined $500m for selling adulterated drugs
May 14, 2013Manufacturing and Production FDA, GMP, Ranbaxy, fine, generics
Ranbaxy’s US subsidiary has agreed to pay fines and penalties totalling $500 million after pleading guilty to charges of manufacturing …
EMA ponders biosimilar guideline
May 14, 2013Research and Development, Sales and Marketing EMA, biosimilars
The European Medicines Agency is thinking about changes to its guidance on similar biological medicines and has published a draft …
Lilly takes $30m hit
May 13, 2013Research and Development, Sales and Marketing enzastaurin, lilly
Eli Lilly has taken a $30 million hit after abandoning late-stage development of its investigational cancer drug enzastaurin. The compound …
Francis at centre of Care Bill
May 13, 2013Sales and Marketing Hunt, Mid Staffs, NHS
The government’s new Care Bill carries a variety of measures designed to ensure that failings such as those at the …
John LaMattina: India’s solution to drug costs
May 13, 2013Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing India, LaMattina, R&D
Drug pricing is a major issue in India. The Indian government believes that the prices of lifesaving drugs shouldn’t be …
New Board member for Misonix
May 13, 2013Manufacturing and Production, Research and Development, Sales and Marketing Misonix
Surgical device company Misonix has announced that Stavros Vizirgianakis has been appointed to its Board of directors.The addition of Vizirgianakis …
Takeda to buy Inviragen
May 10, 2013Research and Development, Sales and Marketing Inviragen, Takeda
Takeda has hit the acquisition trail, putting together a $250 million package to buy private US biopharma firm Inviragen in …
Latest content
AstraZeneca’s Trixeo approved in EU for asthma
ESTEVE CDMO adds $17.5m to Illinois expansion
